Rich; Steven A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Rich; Steven A..The latest application filed is for "fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders".

Company Profile

2.12.12

Rich; Steven A. - Canandaigua NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases Grant 11,419,850 - Rich August 23, 2	2022-08-23
Fixed Dose Combination Of Cholinesterase Inhibitor And A Quaternary Ammonium Antimuscarinic Agent To Treat Neurodegenerative Cognitive Disorders App 20220241254 - Rich; Steven A.	2022-08-04
Glycopyrronium fatty acid salts and methods of making same Grant 10,519,109 - Rich , et al. Dec	2019-12-31
Combined Acetylcholinesterase Inhibitor And Quaternary Ammonium Antimuscarinic Therapy To Alter Progression Of Cognitive Disease App 20190314332 - Rich; Steven A.	2019-10-17
Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases Grant 10,376,493 - Rich A	2019-08-13
Glycopyrronium Fatty Acid Salts and Methods of Making Same App 20180179156 - Rich; Steven A. ; et al.	2018-06-28
Quaternary ammonium anti-cholinergic muscarinic receptor antagonists Grant 9,980,941 - Rich May 29, 2	2018-05-29
Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases App 20160346248 - Rich; Steven A.	2016-12-01
Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium Grant 9,084,753 - Rich July 21, 2	2015-07-21
Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases Grant 9,034,890 - Rich May 19, 2	2015-05-19
Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases Grant 8,969,402 - Rich March 3, 2	2015-03-03
Combined Acetylcholinesterase Inhibitor And Quaternary Ammonium Antimuscarinic Therapy To Alter Progression Of Cognitive Diseases App 20150031897 - Rich; Steven A.	2015-01-29
Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases App 20130172379 - Rich; Steven A.	2013-07-04
Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases App 20130172398 - Rich; Steven A.	2013-07-04
New Uses For Quaternary Ammonium Anticholinergic Muscarinic Receptor Antagonists In Patients Being Treated For Cognitive Impairment Or Acute Delirium App 20120088785 - Rich; Steven A.	2012-04-12
Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium Grant 8,097,633 - Rich January 17, 2	2012-01-17
New Uses For Quaternary Ammonium Anticholinergic Muscarinic Receptor Antagonists In Patients Being Treated For Cognitive Impairment Or Acute Delirium App 20080114014 - Rich; Steven A.	2008-05-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.